Last reviewed · How we verify
Ciprofloxacin 0.3%
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
Ciprofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription. Used for Bacterial conjunctivitis, Corneal ulcers, Other bacterial eye infections.
At a glance
| Generic name | Ciprofloxacin 0.3% |
|---|---|
| Also known as | CETRAXAL OTICO® |
| Sponsor | Indiana University School of Medicine |
| Drug class | Fluoroquinolone antibiotic |
| Target | DNA gyrase, topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Ciprofloxacin works by binding to and inhibiting bacterial DNA gyrase (in gram-negative bacteria) and topoisomerase IV (in gram-positive bacteria), enzymes essential for DNA replication and transcription. This leads to rapid bactericidal activity against a broad spectrum of gram-negative and gram-positive bacteria. The 0.3% ophthalmic formulation is used topically on the eye to treat bacterial infections.
Approved indications
- Bacterial conjunctivitis
- Corneal ulcers
- Other bacterial eye infections
Common side effects
- Local irritation (burning, stinging)
- Conjunctival hyperemia
- Photophobia
- Lid margin crusting
Key clinical trials
- Comparing the Effect of Different Intracanal Dressing on Failed Root Canal Treated Cases on Periapical Healing (PHASE2)
- LiveSpo Navax® Supports the Treatment of Acute Rhinosinusitis and Otitis Media (NA)
- Antibiotic Concentration After Delivery to Middle Ear for Chronic Suppurative Otitis Media
- FST-201 in the Treatment of Acute Otitis Externa (PHASE3)
- Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa (PHASE3)
- FST-201 In The Treatment of Acute Otitis Externa (PHASE3)
- A Phase III Study of Ciprofloxacin Plus Fluocinolone in Acute Otitis Externa (AOE) (PHASE3)
- Evaluation of Treatment Option for Demodicosis in Patients Undergoing Cataract Surgery (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ciprofloxacin 0.3% CI brief — competitive landscape report
- Ciprofloxacin 0.3% updates RSS · CI watch RSS
- Indiana University School of Medicine portfolio CI